Abstract:
Provided herein are methods, compositions, and kits for forming amplification products. In various embodiments provided herein, transposomes comprising transposases are used in forming tagged polynucleotides for downstream amplification and polynucleotide processing steps.
Abstract:
Die Erfindung betrifft Verfahren und Mittel zur Diagnostik von Tumoren, insbesondere zur Frühdiagnostik(Vorsorge)und zur Unterscheidung von benignen und malignen Tumoren mittels PCR, insbesondere in Körperflüssigkeiten. Das erfindungsgemäße Verfahren zeichnet sich durch eine Kombination einer Präamplifikation mittels PCR aus,in der methylierte DNA-Sequenzen stärker amplifiziert werden als nicht-methylierte DNA-Sequenzenund eine anschließende Quantifizierung mittels einer speziellen digitalen PCR, in der deutlich mehr DNA eingesetzt wird, als nach dem Stand der Technik üblich. Wie anhand von Vergleichsdaten gezeigt wird, ermöglicht die Erfindung vorteilhaft eine deutlich zuverlässige Aussage, ob eine maligne Tumorerkrankung vorliegt oder nicht. Die Erfindung eignet sich zum Screening (Vorsorge), zur Verlaufskontrolle einer Tumorerkrankung, insbesondere zum Ausschluss einerminimalen Resterkrankung (MRD) und zur Differentialdiagnose von malignen Karzinomen von benignen Tumoren.
Abstract:
The invention provides compositions and methods for determining whether a subject is predisposed to the disease or condition, or for diagnosing a disease or condition, or for detecting the state of a disease or condition, by detecting the methylation state of the subject's nucleic acids. In addition, the invention provides methods for determining the methylation age of a subject or tissue from a subject or for differentiation between nucleic acids originating from different subjects or tissues. The invention further provides methods for selecting nucleic acid molecules for use in the methods of the invention.
Abstract:
The present invention relates to methods for detecting a chromosomal aneuploidy in a foetus carried by a pregnant female. Such methods are based on one or more of particular configurations and/or detections and/or analyses of two or more regions of DNA, including those that show differential methylation between DNA that originates from cells of a foetus (and/or the placenta of a foetus) and DNA of maternal origin. Such methods utilise a sample taken from said pregnant female, which sample comprises DNA that originates from cells of a foetus and/or the placenta of a foetus in admixture with differently methylated DNA of maternal origin. Such methods have diagnostic, prognostic and/or predictive utility; in particular for the detection/diagnosis of chromosomal aneuploidy, such as a trisomy, in a foetus, and/or for detecting an increased risk of a pregnant female suffering from or developing a pregnancy-associated medical condition. The present invention also relates to compositions, kits, computer program products and other aspects that may be used in, useful for or related to the practice of such methods.
Abstract:
Provided herein is technology relating to the amplification-based detection of bisulfite-treated DNAs and particularly, but not exclusively, to methods and compositions for multiplex amplification of low-level sample DNA prior to further characterization of the sample DNA. The technology further provides methods for isolating DNA from blood or blood product samples, e.g. , plasma samples.
Abstract:
In a first aspect, embodiments disclosed herein provide methods for preparing a sample for sequencing, comprising: treating nucleic acid molecules in the sample to convert at least a portion of unmethylated cytosine residues into uracil residues; and cleaving the nucleic acid molecules at at least a portion of the uracil residues to obtain nucleic acid fragments. Further provided are populations of nucleic acid fragments resulting from a sample treated with the methods disclosed herein.
Abstract:
This disclosure provides methods and materials for determining whether or not an individual is using alcohol, and also for determining whether or not the individual has stopped using alcohol.
Abstract:
The contributions of different tissues to a DNA mixture are determined using methylation levels at particular genomic sites. Tissue-specific methylation levels of M tissue types can be used to deconvolve mixture methylation levels measured in the DNA mixture, to determine fraction contributions of each of the M tissue types. Various types of genomic sites can be chosen to have particular properties across tissue types and across individuals, so as to provide increased accuracy in determining contributions of the various tissue types. The fractional contributions can be used to detect abnormal contributions of a particular tissue, indicating a disease state for the tissue. A differential in fractional contributions for different sizes of DNA fragments can also be used to identify a diseased state of a particular tissue. A sequence imbalance for a particular chromosomal region can be detected in a particular tissue, e.g., identifying a location of a tumor.
Abstract:
This disclosure provides methods and materials for determining whether or not an individual is using alcohol, and also for determining whether or not the individual has stopped using alcohol.
Abstract:
Methods for determining the prognosis of a subject having acute myeloid leukemia (AML) as well as methods of treating AML subjects depending on prognosis.